Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cytosorbents - CTSO

CTSO

Close Chg Chg %
0.87 0.01 1.04%

Closed Market

0.88

+0.01 (1.04%)

Volume: 151.41K

Last Updated:

Dec 11, 2024, 4:00 PM EDT

Trade Now

Company Overview: cytosorbents - CTSO

CTSO Key Data

Open

$0.89

 Day Range

0.82 - 0.92

52 Week Range

0.70 - 2.14

 Market Cap

$47.57M

Shares Outstanding

54.68M

 Public Float

46.93M

Beta

0.57

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.36

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

130.72K

  

CTSO Performance

1 Week
 
 -4.48%
 
1 Month
 
 17.78%
 
3 Months
 
 -19.30%
 
1 Year
 
 -31.91%
 
5 Years
 
 -79.20%
 

CTSO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About cytosorbents - CTSO

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

CTSO At a Glance

CytoSorbents Corp.
305 College Road East
Princeton, New Jersey 08540
Phone 1-732-329-8885 Revenue 36.35M
Industry Medical Specialties Net Income -28,507,394.00
Sector Health Technology 2023 Sales Growth 4.787%
Fiscal Year-end 12 / 2024 Employees 186
View SEC Filings

CTSO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.364
Price to Book Ratio 2.587
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.884
Enterprise Value to Sales 1.479
Total Debt to Enterprise Value 0.341

CTSO Efficiency

Revenue/Employee 195,426.769
Income Per Employee -153,265.559
Receivables Turnover 6.001
Total Asset Turnover 0.605

CTSO Liquidity

Current Ratio 1.767
Quick Ratio 1.514
Cash Ratio 0.971

CTSO Profitability

Gross Margin 61.602
Operating Margin -84.054
Pretax Margin -80.665
Net Margin -78.426
Return on Assets -47.434
Return on Equity -97.212
Return on Total Capital -68.547
Return on Invested Capital -61.817

CTSO Capital Structure

Total Debt to Total Equity 78.681
Total Debt to Total Capital 44.034
Total Debt to Total Assets 32.147
Long-Term Debt to Equity 66.335
Long-Term Debt to Total Capital 37.125
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cytosorbents - CTSO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
41.00M 43.17M 34.69M 36.35M
Sales Growth
+64.35% +5.27% -19.64% +4.79%
Cost of Goods Sold (COGS) incl D&A
11.05M 11.05M 13.96M 13.96M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
660.79K 1.13M 1.13M 2.03M
Depreciation
553.95K 969.19K 937.57K 1.80M
Amortization of Intangibles
106.84K 160.42K 194.06K 222.84K
COGS Growth
+50.09% -0.05% +26.33% +0.01%
Gross Income
29.95M 32.12M 20.73M 22.39M
Gross Income Growth
+70.32% +7.23% -35.45% +8.00%
Gross Profit Margin
+73.05% +74.41% +59.77% +61.60%
2020 2021 2022 2023 5-year trend
SG&A Expense
40.32M 54.86M 51.62M 49.33M
Research & Development
8.81M 16.38M 15.12M 15.73M
Other SG&A
31.51M 38.48M 36.50M 33.60M
SGA Growth
+10.29% +36.06% -5.91% -4.44%
Other Operating Expense
- - - 3.62M
-
Unusual Expense
- - 636.00K 656.00K
-
EBIT after Unusual Expense
(10.37M) (22.74M) (31.52M) (31.21M)
Non Operating Income/Expense
2.61M (2.55M) (2.38M) 2.05M
Non-Operating Interest Income
- - 28.01K 132.60K
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 1.20M 157.89K
-
Interest Expense Growth
- - - +16.20%
-
Gross Interest Expense
- - 1.20M 157.89K
-
Interest Capitalized
- - - -
-
Pretax Income
(8.96M) (25.29M) (33.91M) (29.32M)
Pretax Income Growth
+55.97% -182.17% -34.04% +13.52%
Pretax Margin
-21.86% -58.60% -97.74% -80.66%
Income Tax
(1.13M) (736.00K) (1.09M) (813.74K)
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(7.84M) (24.56M) (32.81M) (28.51M)
Minority Interest Expense
- - - -
-
Net Income
(7.84M) (24.56M) (32.81M) (28.51M)
Net Income Growth
+59.32% -213.36% -33.61% +13.12%
Net Margin Growth
-19.11% -56.89% -94.59% -78.43%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(7.84M) (24.56M) (32.81M) (28.51M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(7.84M) (24.56M) (32.81M) (28.51M)
EPS (Basic)
-0.2019 -0.5664 -0.753 -0.6384
EPS (Basic) Growth
+66.20% -180.53% -32.94% +15.22%
Basic Shares Outstanding
38.82M 43.36M 43.57M 44.66M
EPS (Diluted)
-0.2019 -0.5664 -0.753 -0.6384
EPS (Diluted) Growth
+66.20% -180.53% -32.94% +15.22%
Diluted Shares Outstanding
38.82M 43.36M 43.57M 44.66M
EBITDA
(9.71M) (21.62M) (29.75M) (28.53M)
EBITDA Growth
+47.21% -122.62% -37.65% +4.13%
EBITDA Margin
-23.68% -50.07% -85.77% -78.48%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 10.00
Number of Ratings 2 Current Quarters Estimate -0.065
FY Report Date 12 / 2024 Current Year's Estimate -0.30
Last Quarter’s Earnings -0.08 Median PE on CY Estimate N/A
Year Ago Earnings -0.64 Next Fiscal Year Estimate -0.235
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.07 -0.07 -0.30 -0.24
High Estimates -0.06 -0.06 -0.30 -0.20
Low Estimate -0.07 -0.07 -0.30 -0.27
Coefficient of Variance -10.88 -10.88 0.00 -21.06

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 2
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cytosorbents - CTSO

Date Name Shares Transaction Value
Apr 5, 2024 Kathleen P. Bloch Chief Financial Officer 532,941 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Kathleen P. Bloch Chief Financial Officer 87,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Michael G. Bator Director 44,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Phillip P. Chan Chief Executive Officer; Director 1,164,704 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Phillip P. Chan Chief Executive Officer; Director 124,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Vincent J. Capponi President and COO 665,134 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Vincent J. Capponi President and COO 101,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Edward Raymond Jones Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Alan D. Sobel Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Efthymios N. Deliargyris Chief Medical Officer 409,433 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Efthymios N. Deliargyris Chief Medical Officer 86,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Apr 5, 2024 Jiny Kim Director 22,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Cytosorbents in the News